image description

Krishna Veeraraghavan


Krishna Veeraraghavan

New York +1-212-558-4000+1-212-558-4000 +1-212-558-3588+1-212-558-3588
veera[email protected]
Recognized as “Dealmaker of the Year” and twice named “Dealmaker of the Week” by The American Lawyer, Krishna Veeraraghavan is a partner and member of S&C’s Mergers and Acquisitions Group. Mr. Veeraraghavan has a broad multidisciplinary practice that includes extensive experience in mergers and acquisitions and corporate governance. He has been engaged in many high profile matters that include activism, cross-border transactions, leveraged buyouts, proxy contests and unsolicited bids as an adviser to global leaders such as, AB InBev, AT&T, BHP Billiton, Praxair and Teva Pharmaceuticals. Mr. Veeraraghavan regularly counsels boards of directors and board committees on corporate governance, crisis management and matters affecting corporate policy and strategy. He is an adjunct professor at Columbia Law School. Over the past several years he has advised on a variety of matters including:

Healthcare & Life Sciences
  • Apple Tree Partners as the majority shareholder in Syntimmune, in Syntimmune’s acquisition by Alexion Pharmaceuticals for up to $1.2 billion
  • Seattle Genetics in its $614 million acquisition of Cascadian Therapeutics
  • Syneos Health in its $7.4 billion merger of equals with inVentiv Health
  • Stemcentrx in its $9.8 billion acquisition by AbbVie
  • Teva in its $40.5 billion acquisition of Allergan Generics and $50.5 billion unsolicited proposal for Mylan, later withdrawn
  • Dyax in its $5.9 billion acquisition by Shire
  • Concordia Healthcare in its $3.5 billion acquisition of Amdipharm Mercury and $1.2 billion acquisition of all commercial assets of Covis
  • Synageva in its $8.4 billion acquisition by Alexion
  • Cyberonics in its $1.5 billion merger with Sorin to create LivaNova
  • LabCorp in its $6.1 billion acquisition of Covance
  • Idenix in its $3.85 billion acquisition by Merck
  • Perrigo in its $8.6 billion acquisition of Elan Pharmaceuticals
  • Concho Resources in its $9.5 billion acquisition of RSP Permian
  • Andeavor in the merger of Andeavor Logistics and Western Refining Logistics for $1.8 billion and the repositioning of Andeavor Logistics through an IDR buy-in valued at $4 billion
  • Cheniere Energy in its acquisition of the publicly-held shares of Cheniere Energy Partners LP Holdings not already owned by Cheniere
  • BHP Billiton in its $15.1 billion acquisition of Petrohawk Energy
Consumer & Retail and Industrials
  • General Cable in its $3 billion acquisition by Prysmian Group
  • in its $13.7 billion acquisition of Whole Foods
  • Praxair in its $80 billion merger with Linde
  • Lion Capital in its acquisition of a minority interest in Authentic Brands; acquisition of Spence Diamonds; and $1.5 billion sale of Bumble Bee Foods to Thai Union Frozen Products, later withdrawn
  • Standard Industries in its $2.1 billion acquisition of Braas Monier; $1.1 billion acquisition of Icopal; and acquisition of Quest Construction Products
  • AB InBev in its $123 billion merger with SABMiller and $20.1 billion acquisition of the remaining stake in Grupo Modelo
  • Genesis Robotics in its strategic, controlling investment from Koch Chemical Technology Group, a unit of Koch Industries
  • in its agreement with Plug Power to utilize Plug Power fuel cells and hydrogen technology in its fulfillment network
  • Special Committee of Solera Holdings in connection with its $6.5 billion acquisition by Vista Equity Partners
Real Estate
  • Forest City Realty Trust in its $11.4 billion acquisition by Brookfield Asset Management and agreement with Starboard Value to reconstitute of its Board of Directors
  • American Casino & Entertainment Properties in its $850 million acquisition by Golden Entertainment
  • Special Committee of Forest City Realty Trust in connection with the company's agreement to declassify its common stock and its settlement with Scopia Capital

Mr. Veeraraghavan is consistently recognized as a leading adviser by Chambers USA, Legal 500 and New York Super Lawyers. Recent accolades include:
  • “Healthcare Trailblazer” by The National Law Journal (2019)
  • “Dealmaker of the Year” by The American Lawyer – Amazon’s acquisition of Whole Foods (2018)
  • “Retail & E-Commerce MVP” by Law360 (2017)
  • “Life Sciences MVP” by Law360 (2015 & 2016)
  • “Transatlantic Rising Star” by The American Lawyer (2016)
  • “Dealmaker of the Week” by The American Lawyer – LabCorp’s acquisition of Covance (2015)
  • “Rising Star” by Law360 (2014) and New York Law Journal (2015)
  • “Highly Regarded Lawyer” by IFLR1000
  • “Dealmaker of the Week” by The American Lawyer – Synageva BioPharma’s acquisition by Alexion Pharmaceuticals (2014)
  • Empire State Counsel Honoree for Pro bono Service by the New York State Bar Association (2014)
  • Named among the “Best Lawyers Under 40” by The M&A Advisor (2012) and the National Asian Pacific American Bar Association (2014)
  • Finalist for “Legal Advisor of the Year” by The M&A Advisor (2013)
  • One of four “Rising Stars” (2013) by the Minority Corporate Counsel Association
Professional Activities and Community Involvement

Mr. Veeraraghavan is involved with the following organizations:
  • Member of the Council on Foreign Relations
  • Member of the Dean’s Advisory Council of Princeton University
  • Adjunct professor and member of the Steering Committee of the Board of Visitors at Columbia Law School
  • Member of the board of trustees at Ethical Culture Fieldston School
  • Member of the board of directors of South Asian Youth Action